Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Suzhou Innovent Signs $2 Billion-plus Bi-Specific/CAR-T Development Deal with Roche

publication date: Jun 9, 2020

Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Innovent will use Roche's technologies to discover and develop specific 2:1 T-cell bispecific antibodies (TCB) and universal CAR-T therapies for hematological and solid cancers. Innovent will make upfront and milestone payments for the rights, and it will develop the candidates. Roche will have an option to license each product for ex-China development and commercialization. If Roche exercises all of its options, it will pay $140 million for the options plus $1.96 billion in milestones if all products are successfully commercialized. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.